Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Chagas Disease

Chagas Disease

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Chagas Disease

6 trials tracked for Chagas Disease: 3 in phase 3 or 4 and 3 with published results. The most-cited published study has 516 citations.

6Trials tracked
3Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 4 1 Phase 3 2 Phase 2 1 Other / NA 2
  1. Phase 3 A Study to Learn How Well Nifurtimox Works and How Safe it is in Children Aged 0 to 17 Years With Chagas' Disease, an Inflammatory, Infectious Disease Caused by the Parasite Trypanosoma Cruzi Completed · 516 cited
  2. Phase 3 Short-course Benznidazole Treatment to Reduce Trypanosoma Cruzi Parasitic Load in Women of Reproductive Age Completed · 51 cited
  3. Phase 4 Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC Completed · 14 cited
  4. Phase 2 A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267) Completed
  5. N/A Assessment of Speckle Tracking Strain Predictive Value for Myocardial Fibrosis in Chagas Disease Completed
  6. N/A Abbott ESA Chagas Assay Post-Market Study Completed

Showing the 6 most-cited and recently-updated of 6 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Chagas Disease: what the trials found

Clinical trials evaluating heart failure management (Sacubitril/valsartan) demonstrated a 23.8% to 25.4% mortality rate from cardiovascular causes and hospitalization rates of 22.1% to 24.1% for worsening heart failure.

In the treatment of Chagas disease, Benznidazole showed significant results with low parasite loads (0) at 10 months post-treatment; however, it was associated with a higher rate of serious adverse events leading to treatment discontinuation compared to other outcomes in that cohort.

Nifurtimox demonstrated a sero-reduction or conversion rate of 32.9% and 18.9% in Part 1 of its respective trial, with varying success in concentration tests for T. Cruzi in pediatric populations.

Recent results — preliminary, needs further review

  • Posaconazole results (82.1% to 86.7% successful response via qPCR) are not yet corroborated.
  • Correlation between longitudinal global strain and myocardial fibrosis is not yet corroborated.
  • Testing of donor specimens with ESA Chagas is not yet corroborated.

For the clinician treating this condition

  • Sacubitril/valsartan shows consistent outcomes in reducing hospitalization for heart failure compared to standard measures.
  • Benznidazole and Nifurtimox are established interventions for Chagas disease, though Benznidazole is associated with specific risks of treatment discontinuation.
  • Evidence for Posaconazole and other experimental protocols remains unconfirmed.

AI synthesis of 0 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
One Health approach in Chagas disease remains fragmented, review finds
Neurology Meta-analysis
One Health approach in Chagas disease remains fragmented, review finds One Health Approach Shows Gaps in Chagas Disease Research
A systematic review of 68 documents found that the One Health approach in Chagas disease studies predominantly focuses on animal health (41.…
A review of research shows that most studies on Chagas disease focus only on animal health rather than integrating human and environmental f…
Frontiers Jun 17, 2026
Chagas disease associated with higher in-hospital mortality in adults hospitalized with heart failure
Cardiology Cohort
Chagas disease associated with higher in-hospital mortality in adults hospitalized with heart failure Heart Failure Patients With Chagas Face Higher Death Risk In Hospital
This cohort study analyzed 910,128 heart failure hospitalizations within the Brazilian Unified Health System.
A massive study of nearly a million patients reveals that Chagas disease makes heart failure much more deadly inside the hospital.
medRxiv Apr 29, 2026
Systematic review finds evidence gap for amiodarone in chronic Chagas cardiomyopathy
Drug Pipeline Meta-analysis
Systematic review finds evidence gap for amiodarone in chronic Chagas cardiomyopathy Review finds major research gap on heart drug amiodarone for Chagas disease
A systematic review and bibliometric analysis of 52 articles identified a significant literature gap regarding amiodarone therapy for chroni…
A review of 52 studies found a significant lack of rigorous clinical research on using the heart drug amiodarone for Chagas cardiomyopathy.
Frontiers Apr 6, 2026
Case report describes likely first autochthonous Chagas disease case in Missouri blood donor
Hematology
Case report describes likely first autochthonous Chagas disease case in Missouri blood donor Blood donor in Missouri tests positive for Chagas disease, likely first local case
A case report describes a blood donor in Missouri with a positive screening result for Trypanosoma cruzi antibodies.
A Missouri blood donor likely represents the first local case of Chagas disease, a parasite usually found in Latin America.
CDC Apr 2, 2026

Questions about Chagas Disease

Can a blood donor in Missouri get Chagas Disease from donating blood?

A Missouri blood donor can transmit Chagas disease if they have the parasite, as shown by a 2017 case where a donor tested positive for the disease-causing parasite.

Full answer →